

10/582082

APS Rec'd PCT/PTO 08 JUN 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Katsura FUNAYAMA et al. : Mail Stop: PCT

Serial No. NEW : Attorney Docket No. 2006\_0715A

Filed June 8, 2006 :

MARINE ALGAE EXTRACT AND LIPASE  
INHIBITOR CONTAINING THE SAME  
[Corresponding to PCT/JP2004/018369  
Filed December 9, 2004]

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- each U.S. Patent and U.S. Patent application publication;
- each reference previously cited in the international application PCT/\_\_\_\_\_; and/or
- each reference previously cited in prior parent application Serial No. \_\_\_\_\_.

1a.  This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.G./  
ATTACHMENT C

10/582082

AP3 Rec'd PCT/PTO 08 JUN 2001

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

- 1b.  This Information Disclosure Statement is submitted  
after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:  
(1)  the certification of paragraph 2 below is provided, **or**  
(2)  the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c.  This Information Disclosure Statement is submitted:  
after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:  
**the certification of paragraph 2 below is provided, and**  
**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified
- a.  that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
  - b.  that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

10/582082  
AP3 Rec'd PCT/PTO 08 JUN 2006

3.  Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
  - a.  a full or partial English language translation submitted herewith,
  - b.  a foreign patent office search report (in the English language) submitted herewith,
  - c.  the concise explanation contained in the specification of the present application at page,
  - d.  the concise explanation set forth in the attached English language abstract,
  - e.  the concise explanation set forth below or on a separate sheet attached to the reference:
5.  A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Katsura FUNAYAMA et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
June 8, 2006

10/58208

AP9Rec'd PCT/PTO 08 JUN 2009

Sheet 1 of 1

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (*modified*)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(*Use several sheets if necessary*)

Date Submitted to PTO: June 8, 2006

ATTY DOCKET NO.  
2006\_0715ASERIAL NO.  
NEWAPPLICANT  
Katsura FUNAYAMA et al.FILING DATE  
June 8, 2006

GROUP 4161

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2004/0029828	2/2004	Nishiyama et al.			Corresponds to AL
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AJ	2003-160505	6/2003	JP			Abstract
	AK	2000-072642	3/2000	JP			Abstract
	AL	2002/22140	3/2002	WO			
	AM	5-284937	11/1993	JP			Abstract
	AN						

OTHER DOCUMENT(S) (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	AO	D. Ren et al., "Study on Antihypertensive and Antihyperlipidemic Effects of Marine Algae", Fisheries Science, Vol. 60, No. 1, pp. 83-88, 1994.
	AP	
	AQ	

EXAMINER

/Brian Gulledge/

DATE CONSIDERED

06/05/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.G./